Janus Henderson Group PLC Schedule 13G passive stakes

Janus Henderson Group plc has filed an amended Schedule 13G, reporting an 8.8% beneficial ownership stake in DBV Technologies S.A., totaling 20,469,392 common shares.

Janus Henderson Group plc has filed a Schedule 13G, reporting a 12.2% beneficial ownership stake in CAMP4 Therapeutics Corp.

Janus Henderson Group plc has filed an amended Schedule 13G, reporting beneficial ownership of 2.6% of DBV Technologies S.A. common stock.

Janus Henderson Group plc has reported a 9.99% passive beneficial ownership stake in Tenax Therapeutics, Inc., totaling 623,733 shares.

Janus Henderson Group plc has reported a 9.99% beneficial ownership stake in Pasithea Therapeutics Corp., primarily through shared voting and dispositive power.

Janus Henderson Group plc and its affiliates have reported a 9.99% beneficial ownership stake in Palisade Bio, Inc. common stock.

Janus Henderson Group plc and its affiliates have reported a 9.99% beneficial ownership stake in Palatin Technologies Inc., primarily through common stock and exercisable warrants.

Janus Henderson Group plc has reported a 9.99% beneficial ownership stake in Ovid Therapeutics Inc., holding over 7.1 million shares.

Janus Henderson Group plc has reported a 6.0% beneficial ownership stake in Ocugen, Inc., holding 20 million shares of common stock.

Janus Henderson Group plc has reported a 9.99% beneficial ownership stake in LEXEO Therapeutics, Inc., holding 7,291,434 shares of common stock.

Janus Henderson Group plc has reported a 9.99% beneficial ownership stake in INOVIO PHARMACEUTICALS, INC., holding 6,666,295 shares of common stock.

Janus Henderson Group plc has reported a 9.99% beneficial ownership stake in IMMUNIC, INC., including common and pre-funded warrants.

Janus Henderson Group plc has reported a 9.99% beneficial ownership stake in Equillium, Inc., including common stock and exercisable warrants.

Janus Henderson Group plc has reported a significant 9.5% beneficial ownership stake in DBV Technologies S.A., holding over 20 million shares.

Janus Henderson Group plc has reported an 8.2% beneficial ownership stake in Biomea Fusion, Inc., holding 3,750,000 shares of common stock.

Janus Henderson Group plc and its affiliate have filed an amended Schedule 13G, disclosing a beneficial ownership of 9.99% in Benitec Biopharma Inc. common stock.

Janus Henderson Group plc has reported a beneficial ownership of 8.2% in Assembly Biosciences, Inc., holding 1,341,508 shares of common stock.

Janus Henderson Group plc has filed an Amendment No. 4 to Schedule 13G, reporting a 5.5% beneficial ownership stake in Avidity Biosciences, Inc.

Janus Henderson Group plc has disclosed an increased beneficial ownership of 10.6% in Mirum Pharmaceuticals, Inc. common stock.

Janus Henderson Group plc has reported an 11.9% beneficial ownership stake in Travere Therapeutics, Inc. common stock.

Janus Henderson Group plc and its affiliated funds reported an increased passive ownership stake of 19.5% in Monopar Therapeutics Inc. common stock.

Janus Henderson Group plc reports an increased beneficial ownership of 7.3% in Maze Therapeutics, Inc., holding 3,206,472 common shares.

Janus Henderson Group plc, through its subsidiaries, reported an 11.3% beneficial ownership stake in LEXEO THERAPEUTICS, INC. as of September 30, 2025.

Janus Henderson Group plc has reported a 5.3% beneficial ownership stake in Ligand Pharmaceuticals Incorporated common stock as of September 30, 2025.

Janus Henderson Group plc has filed an amended Schedule 13G, reporting a 5.4% beneficial ownership stake in Sensient Technologies Corporation.

Janus Henderson Group PLC has filed an amended Schedule 13G, reporting a beneficial ownership of 5.6% in Rentokil Initial PLC as of September 30, 2025.

Janus Henderson Group plc has filed an amended Schedule 13G, reporting a 5.7% beneficial ownership stake in Ardelyx, Inc. common stock.

Janus Henderson Group plc has filed an amended Schedule 13G, reporting a beneficial ownership of 5.9% in OSI Systems, Inc. common stock.

Janus Henderson Group plc has filed an amendment to its Schedule 13G, disclosing a 6.0% beneficial ownership stake in Dayforce, Inc.'s common stock.

Janus Henderson Group plc has reported a 6.1% beneficial ownership stake in Revolution Medicines, Inc., holding over 11 million shares.